Eupraxia OTC Stock Today

EPRXF -  USA Stock  

USD 2.30  0.00  0.00%

Market Performance
9 of 100
Odds Of Distress
Over 56
Eupraxia Pharmaceuticals is trading at 2.30 as of the 19th of January 2022, a No Change since the beginning of the trading day. The stock's lowest day price was 2.3. Eupraxia Pharmaceuticals has over 56 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Eupraxia Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of December 2021 and ending today, the 19th of January 2022. Click here to learn more.
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada. The company has 14.24 M outstanding shares. More on Eupraxia Pharmaceuticals
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Eupraxia Pharmaceuticals OTC Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Eupraxia Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Eupraxia Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Eupraxia Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (19.41 M).
Eupraxia Pharmaceuticals has accumulated about 33.67 M in cash with (11.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 13.0% of the company shares are held by company insiders
Latest headline from finance.yahoo.com: Eupraxia Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference - Yahoo Finance
Legal NameEupraxia Pharmaceuticals
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Eupraxia Pharmaceuticals' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong HoldFairly Valued
Eupraxia Pharmaceuticals [EPRXF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with current market capitalization of 32.76 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Eupraxia Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Eupraxia Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Eupraxia Pharmaceuticals classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 14.24 M outstanding shares. Eupraxia Pharmaceuticals has accumulated about 33.67 M in cash with (11.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Eupraxia Pharmaceuticals Probability Of Bankruptcy
Ownership
Eupraxia Pharmaceuticals retains a total of 14.24 Million outstanding shares. Eupraxia Pharmaceuticals shows 13.45 percent if its outstanding shares held by insiders and 13.45 percent owned by other corporate entities . Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Eupraxia Ownership Details

Eupraxia Stock Price Odds Analysis

What are Eupraxia Pharmaceuticals' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Eupraxia Pharmaceuticals jumping above the current price in 90 days from now is about 23.83%. The Eupraxia Pharmaceuticals probability density function shows the probability of Eupraxia Pharmaceuticals otc stock to fall within a particular range of prices over 90 days. Assuming the 90 days horizon Eupraxia Pharmaceuticals has a beta of 0.111 suggesting as returns on the market go up, Eupraxia Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Eupraxia Pharmaceuticals will be expected to be much smaller as well. Additionally, the company has an alpha of 0.0854, implying that it can generate a 0.0854 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 2.3HorizonTargetOdds Up 2.3 
75.51%90 days
 2.30 
23.83%
Based on a normal probability distribution, the odds of Eupraxia Pharmaceuticals to move above the current price in 90 days from now is about 23.83 (This Eupraxia Pharmaceuticals probability density function shows the probability of Eupraxia OTC Stock to fall within a particular range of prices over 90 days) .

Eupraxia Pharmaceuticals Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Eupraxia Pharmaceuticals market risk premium is the additional return an investor will receive from holding Eupraxia Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Eupraxia Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Eupraxia Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Eupraxia Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.

Eupraxia Stock Against Markets

Picking the right benchmark for Eupraxia Pharmaceuticals otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Eupraxia Pharmaceuticals otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Eupraxia Pharmaceuticals is critical whether you are bullish or bearish towards Eupraxia Pharmaceuticals at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Eupraxia Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Companies Directory Now

   

Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
All  Next Launch Module
Continue to Investing Opportunities. Note that the Eupraxia Pharmaceuticals information on this page should be used as a complementary analysis to other Eupraxia Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Eupraxia OTC Stock analysis

When running Eupraxia Pharmaceuticals price analysis, check to measure Eupraxia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eupraxia Pharmaceuticals is operating at the current time. Most of Eupraxia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eupraxia Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Eupraxia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eupraxia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Is Eupraxia Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eupraxia Pharmaceuticals. If investors know Eupraxia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eupraxia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Eupraxia Pharmaceuticals is measured differently than its book value, which is the value of Eupraxia that is recorded on the company's balance sheet. Investors also form their own opinion of Eupraxia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eupraxia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eupraxia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eupraxia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eupraxia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Eupraxia Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eupraxia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.